chloroquine has been researched along with tafenoquine in 35 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 6 (17.14) | 18.2507 |
| 2000's | 7 (20.00) | 29.6817 |
| 2010's | 18 (51.43) | 24.3611 |
| 2020's | 4 (11.43) | 2.80 |
| Authors | Studies |
|---|---|
| Ager, A; Ellis, W; Guan, J; Kyle, D; Lin, AJ; Milhous, W; Sacci, J; Zhang, Q | 1 |
| Fitos, I; Mády, G; Visy, J; Zsila, F | 1 |
| García-Mera, X; González-Díaz, H; Prado-Prado, FJ | 1 |
| Carvalho, L; Castanys, S; Gamarro, F; Manzano, JI; Pérez-Victoria, JM | 1 |
| Kozar, MP; Lin, AJ; Luong, T; Melendez, V; Sathunuru, R; Zhang, L | 1 |
| Kozar, MP; Li, Q; Lin, AJ; Liu, X; Melendez, V; O'Neil, MT; Wang, X | 1 |
| Avery, VM; Sykes, ML | 1 |
| Iyer, PS; Kannan, M; Khan, FR; Raichurkar, AV | 1 |
| Trigg, PI | 1 |
| Milhous, WK; Peters, W; Robinson, BL | 1 |
| Fleck, SL; Peters, W; Robinson, BL | 1 |
| Cooper, RD; Kyle, DE; Nuzum, EO; Obaldia, N; Rieckmann, KH; Rossan, RN; Shanks, GD | 1 |
| Braitman, DJ; Brewer, TG; Brueckner, RP; Chokejindachai, W; Heppner, DG; Horton, J; Kyle, DE; Looareesuwan, S; Milhous, WK; Schuster, BG; Tang, DB; Viriyavejakul, P; Walsh, DS; Wilairatana, P | 1 |
| Peters, W | 1 |
| Peters, W; Robinson, BL; Stewart, LB | 1 |
| Chambers, JA | 1 |
| Brewer, TG; Heppner, DG; Krudsood, S; Looareesuwan, S; Phumratanaprapin, W; Silachamroon, U; Siriyanonda, D; Tang, DB; Walsh, DS; Wilairatana, P | 1 |
| Prajakwong, S; Sirichaisinthop, J; Vollnberg, A; Wernsdorfer, G; Wernsdorfer, WH; Wiedermann, G | 1 |
| Edstein, MD; Kitchener, S; Nasveld, P | 1 |
| Imre, T; Iványi, R; Jicsinszky, L; Mizsei, R; Németh, K; Simonyi, M; Szemán, J; Szente, L; Tárkányi, G; Varga, E; Visy, J | 1 |
| Cozens, S; Dow, GS; Gettayacamin, M; Hansukjariya, P; Imerbsin, R; Kenworthy, D; Komcharoen, S; Kyle, D; Milhous, W; Miller, A; Ohrt, C; Sattabongkot, J; Veazey, J | 1 |
| Fernando, D; Rajapakse, S; Rodrigo, C | 2 |
| Baptiste-Brown, S; Beelen, AP; Duparc, S; Griffith, S; Harrell, E; Hughes, A; Kleim, JP; Miller, AK; Möhrle, JJ; Ohrt, C; Stinnett, S; Webster, A; Ye, L | 1 |
| Baresel, PC; Campo, B; Magill, AJ; Ohrt, C; Rochford, R; Sampath, A; Tekwani, BL; Walker, LA | 1 |
| Arthur, P; Carter, N; Chuenchom, N; Duparc, S; Green, JA; Gupta, SK; Kellam, L; Kleim, JP; Kochar, SK; Krudsood, S; Lacerda, MV; Llanos-Cuentas, A; Möhrle, JJ; Rueangweerayut, R; Ugwuegbulam, C | 1 |
| Nosten, F; Price, RN | 1 |
| Fuehrer, HP; Ganesh, D; Graninger, W; Haque, R; Khan, WA; Noedl, H; Starzengruber, P; Swoboda, P | 1 |
| Beck, HP; Carter, N; Duparc, S; Green, JA; Koh, G; Krudsood, S; Lacerda, MV; Llanos-Cuentas, A; Osorio, L; Rubio, JP; Rueangweerayut, R; Wampfler, R | 1 |
| Beaumont, C; Carter, N; Duparc, S; Green, JA; Koh, GC; Krudsood, S; Llanos-Cuentas, A; Rubio, JP; Rueangweerayut, R; St Jean, PL; Taylor, M; Xue, Z | 1 |
| Abdissa, A; Abebe, C; Angus, B; Batista Pereira, D; Beck, HP; Brand, F; Breton, JJ; Brito, MAM; Buathong, N; Casapía, M; Chuquiyauri, R; Clover, DD; Costa, MRF; Diro, E; Duparc, S; Espino, FEJ; Fletcher, K; Getie, S; Green, JA; Hardaker, E; Jones, SW; Kellam, LM; Kleim, JP; Koh, GCKW; Krudsood, S; Lacerda, MVG; Llanos-Cuentas, A; Lon, C; Mia, RZ; Mohamed, K; Mohammed, R; Monteiro, WM; Noedl, H; Rousell, VM; Saunders, DL; Tada, MS; Ugwuegbulam, CO; Val, F; Wubie, KM; Yilma, D; Zeynudin, A | 1 |
| Angus, B; Aruachan, S; Bancone, G; Breton, JJ; Brito, MAM; Casapía, M; Chu, CS; Chuquiyauri, R; Clover, DD; Costa, MRF; Craig, G; Duparc, S; Green, JA; Hardaker, E; Hien, TT; Jones, SW; Kendall, L; Koh, GCKW; Lacerda, MVG; Llanos-Cuentas, A; Mohamed, K; Monteiro, WM; Namaik-Larp, C; Nguyen, CH; Nosten, FH; Papwijitsil, R; Rousell, VM; Val, F; Vélez, ID; Villegas, MF; Wilches, VM | 1 |
| Devine, A; Dittrich, S; Howes, RE; Ley, B; Moore, KA; Price, DJ; Price, RN; Simpson, JA | 1 |
| Breton, JJ; Chau, NH; Duparc, S; Ernest, TB; Goyal, N; Green, JA; Hien, TT; Hoa, NT; Jones, SW; Martin, A; Mohamed, K; Rolfe, K; Rousell, VM; Sharma, H; Tan, LK; Taylor, M; Vélez, ID | 1 |
| Baird, JK; Berni, A; Budiman, W; Cedar, E; Chand, K; Crenna-Darusallam, C; Duparc, S; Ekawati, LL; Elyazar, I; Fernando, D; Fletcher, K; Goyal, N; Green, JA; Instiaty, I; Jones, S; Kleim, JP; Lardo, S; Martin, A; Noviyanti, R; Prasetya, CB; Rolfe, K; Santy, YW; Satyagraha, AW; Sharma, H; Soebandrio, A; Subekti, D; Sutanto, I; Tan, LK; Taylor, M | 1 |
5 review(s) available for chloroquine and tafenoquine
| Article | Year |
|---|---|
Approaches to protozoan drug discovery: phenotypic screening.
Topics: Drug Discovery; Humans; Molecular Structure; Neglected Diseases; Phenotype; Plasmodium falciparum; Protozoan Infections; Trypanocidal Agents; Trypanosoma brucei brucei; Trypanosoma cruzi | 2013 |
The evolution of tafenoquine--antimalarial for a new millennium?
Topics: Aminoquinolines; Antimalarials; Chloroquine; Drug Resistance; Humans; Malaria; Primaquine | 1999 |
Military aviators, special operations forces, and causal malaria prophylaxis.
Topics: Aminoquinolines; Antimalarials; Atovaquone; Aviation; Chloroquine; Doxycycline; Drug Combinations; Humans; Malaria; Mefloquine; Military Personnel; Naphthoquinones; Primaquine; Proguanil; United States | 2003 |
Primaquine in vivax malaria: an update and review on management issues.
Topics: Aminoquinolines; Antimalarials; Artemisinins; Chloroquine; Clinical Trials as Topic; Drug Resistance; Glycogen Storage Disease Type I; Hemolysis; Humans; Malaria, Vivax; Plasmodium vivax; Primaquine | 2011 |
Tafenoquine for preventing relapse in people with Plasmodium vivax malaria.
Topics: Adult; Aminoquinolines; Antimalarials; Chloroquine; Drug Administration Schedule; Glucosephosphate Dehydrogenase Deficiency; Humans; Malaria, Vivax; Parasitemia; Placebos; Primaquine; Randomized Controlled Trials as Topic; Recurrence; Secondary Prevention | 2020 |
10 trial(s) available for chloroquine and tafenoquine
| Article | Year |
|---|---|
Randomized dose-ranging study of the safety and efficacy of WR 238605 (Tafenoquine) in the prevention of relapse of Plasmodium vivax malaria in Thailand.
Topics: Adolescent; Adult; Aminoquinolines; Antimalarials; Chloroquine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Malaria, Vivax; Male; Prospective Studies; Recurrence; Thailand | 1999 |
Randomized trial of 3-dose regimens of tafenoquine (WR238605) versus low-dose primaquine for preventing Plasmodium vivax malaria relapse.
Topics: Adolescent; Adult; Aminoquinolines; Antimalarials; Chloroquine; Dose-Response Relationship, Drug; Female; Humans; Malaria, Vivax; Male; Methemoglobin; Middle Aged; Primaquine; Risk; Secondary Prevention; Time Factors | 2004 |
Pharmacokinetic interactions and safety evaluations of coadministered tafenoquine and chloroquine in healthy subjects.
Topics: Administration, Oral; Adolescent; Adult; Aminoquinolines; Antimalarials; Area Under Curve; Chloroquine; Double-Blind Method; Drug Interactions; Drug Therapy, Combination; Female; Glucosephosphate Dehydrogenase; Humans; Male; Middle Aged; Polymorphism, Single Nucleotide; Young Adult | 2013 |
Tafenoquine plus chloroquine for the treatment and relapse prevention of Plasmodium vivax malaria (DETECTIVE): a multicentre, double-blind, randomised, phase 2b dose-selection study.
Topics: Adolescent; Adult; Aged; Aminoquinolines; Antimalarials; Brazil; Chloroquine; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Humans; India; Malaria, Vivax; Male; Middle Aged; Peru; Primaquine; Secondary Prevention; Thailand; Treatment Outcome; Young Adult | 2014 |
Estimation of the Antirelapse Efficacy of Tafenoquine, Using Plasmodium vivax Genotyping.
Topics: Aminoquinolines; Antimalarials; Chloroquine; Dose-Response Relationship, Drug; Double-Blind Method; Genotype; Humans; Malaria, Vivax; Plasmodium vivax; Primaquine; Secondary Prevention | 2016 |
Tafenoquine treatment of Plasmodium vivax malaria: suggestive evidence that CYP2D6 reduced metabolism is not associated with relapse in the Phase 2b DETECTIVE trial.
Topics: Aminoquinolines; Antimalarials; Chloroquine; Cytochrome P-450 CYP2D6; Female; Humans; Malaria, Vivax; Primaquine; Treatment Outcome | 2016 |
Single-Dose Tafenoquine to Prevent Relapse of Plasmodium vivax Malaria.
Topics: Adolescent; Adult; Aminoquinolines; Antimalarials; Chloroquine; Cytochrome P-450 CYP2D6; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; Female; Glucosephosphate Dehydrogenase; Hemoglobins; Humans; Intention to Treat Analysis; Kaplan-Meier Estimate; Logistic Models; Malaria, Vivax; Male; Parasitemia; Plasmodium vivax; Primaquine; Secondary Prevention | 2019 |
Tafenoquine versus Primaquine to Prevent Relapse of Plasmodium vivax Malaria.
Topics: Adolescent; Adult; Aminoquinolines; Antimalarials; Chloroquine; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; Female; Glucosephosphate Dehydrogenase; Glucosephosphate Dehydrogenase Deficiency; Hemoglobins; Humans; Kaplan-Meier Estimate; Malaria, Vivax; Male; Parasitemia; Plasmodium vivax; Primaquine; Prospective Studies; Secondary Prevention | 2019 |
Tafenoquine exposure assessment, safety, and relapse prevention efficacy in children with Plasmodium vivax malaria: open-label, single-arm, non-comparative, multicentre, pharmacokinetic bridging, phase 2 trial.
Topics: Adolescent; Aminoquinolines; Antimalarials; Area Under Curve; Child; Child, Preschool; Chloroquine; Female; Humans; Malaria, Vivax; Male; Recurrence; Secondary Prevention; Tablets | 2022 |
Tafenoquine co-administered with dihydroartemisinin-piperaquine for the radical cure of Plasmodium vivax malaria (INSPECTOR): a randomised, placebo-controlled, efficacy and safety study.
Topics: Antimalarials; Artemisinins; Chloroquine; Drug Therapy, Combination; Humans; Malaria; Malaria, Vivax; Plasmodium vivax; Primaquine; Quinolines | 2023 |
20 other study(ies) available for chloroquine and tafenoquine
| Article | Year |
|---|---|
Unambiguous synthesis and prophylactic antimalarial activities of imidazolidinedione derivatives.
Topics: Administration, Oral; Animals; Antimalarials; Carbamates; Guanidines; Imidazoles; Imidazolidines; Malaria; Male; Mice; Plasmodium falciparum; Plasmodium yoelii; Structure-Activity Relationship | 2005 |
Selective plasma protein binding of antimalarial drugs to alpha1-acid glycoprotein.
Topics: Antimalarials; Binding Sites; Chromatography, Affinity; Circular Dichroism; Humans; Molecular Structure; Orosomucoid; Protein Binding; Serum Albumin; Spectrophotometry; Stereoisomerism; Structure-Activity Relationship | 2008 |
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
Topics: Antiparasitic Agents; Molecular Structure; Neural Networks, Computer; Parasitic Diseases; Quantitative Structure-Activity Relationship; Species Specificity; Thermodynamics | 2010 |
Increased glycolytic ATP synthesis is associated with tafenoquine resistance in Leishmania major.
Topics: Adenosine Triphosphate; Aminoquinolines; Antiprotozoal Agents; Drug Resistance; Glycolysis; Leishmania major; Pyruvate Kinase | 2011 |
New imidazolidinedione derivatives as antimalarial agents.
Topics: Animals; Antimalarials; Humans; Imidazolidines; Macaca mulatta; Mice; Molecular Structure; Plasmodium berghei; Plasmodium cynomolgi; Plasmodium falciparum; Structure-Activity Relationship | 2011 |
Synthesis and antimalarial activity of 2-guanidino-4-oxoimidazoline derivatives.
Topics: Administration, Oral; Animals; Antimalarials; Guanidines; Imidazolidines; Imidazolines; Macaca mulatta; Malaria; Mice; Plasmodium berghei; Plasmodium cynomolgi; Plasmodium falciparum; Prodrugs; Structure-Activity Relationship | 2011 |
Synthesis and in vitro evaluation of novel 8-aminoquinoline-pyrazolopyrimidine hybrids as potent antimalarial agents.
Topics: Aminoquinolines; Antimalarials; Humans; Malaria, Falciparum; Molecular Docking Simulation; Parasitic Sensitivity Tests; Plasmodium falciparum; Pyrazoles; Pyrimidines; Structure-Activity Relationship | 2015 |
Drug use and design in the nineties.
Topics: Aminoquinolines; Amodiaquine; Antimalarials; Artemisinins; Calcium Channel Blockers; Chloroquine; Humans; Malaria; Mefloquine; Naphthoquinones; Phenanthrenes; Primaquine; Quinine; Sesquiterpenes; Sulfadoxine | 1991 |
The chemotherapy of rodent malaria. LI. Studies on a new 8-aminoquinoline, WR 238,605.
Topics: Aminoquinolines; Animals; Antimalarials; Chloroquine; Drug Evaluation, Preclinical; Drug Resistance; Drug Synergism; Malaria; Mice; Plasmodium berghei; Plasmodium yoelii | 1993 |
The chemotherapy of rodent malaria. LIV. Combinations of 'Fenozan B07' (Fenozan-50F), a difluorinated 3,3'-spirocyclopentane 1,2,4-trioxane, with other drugs against drug-sensitive and drug-resistant parasites.
Topics: Aminoquinolines; Animals; Antimalarials; Chloroquine; Drug Antagonism; Drug Resistance; Drug Synergism; Drug Therapy, Combination; Malaria; Mefloquine; Mice; Naphthyridines; Parasitemia; Phenanthrenes; Phenylpropionates; Plasmodium berghei; Plasmodium yoelii | 1997 |
WR 238605, chloroquine, and their combinations as blood schizonticides against a chloroquine-resistant strain of Plasmodium vivax in Aotus monkeys.
Topics: Aminoquinolines; Animals; Antimalarials; Aotus trivirgatus; Chloroquine; Drug Resistance; Drug Therapy, Combination; Malaria, Vivax; Parasitemia | 1997 |
The chemotherapy of rodent malaria. LXI. Drug combinations to impede the selection of drug resistance, part 4: the potential role of 8-aminoquinolines.
Topics: Aminoquinolines; Animals; Antimalarials; Chloroquine; Disease Models, Animal; Drug Resistance; Drug Therapy, Combination; Malaria; Malaria, Falciparum; Malaria, Vivax; Mefloquine; Mice; Plasmodium berghei; Plasmodium chabaudi; Plasmodium yoelii; Primaquine; Time Factors | 2003 |
In-vitro interaction of tafenoquine and chloroquine in Plasmodium falciparum from northwestern Thailand.
Topics: Adolescent; Adult; Aminoquinolines; Animals; Antimalarials; Cell Proliferation; Chloroquine; Dose-Response Relationship, Drug; Drug Combinations; Drug Evaluation; Humans; Malaria, Falciparum; Plasmodium falciparum; Species Specificity; Thailand | 2003 |
Tafenoquine for the treatment of recurrent Plasmodium vivax malaria.
Topics: Adult; Aminoquinolines; Antimalarials; Chloroquine; Humans; Malaria, Vivax; Recurrence | 2007 |
Enantiomeric separation of antimalarial drugs by capillary electrophoresis using neutral and negatively charged cyclodextrins.
Topics: Aminoquinolines; Anions; Antimalarials; beta-Cyclodextrins; Chloroquine; Cyclodextrins; Electrophoresis, Capillary; Humans; Magnetic Resonance Spectroscopy; Mass Spectrometry; Mefloquine; Primaquine; Stereoisomerism | 2011 |
Radical curative efficacy of tafenoquine combination regimens in Plasmodium cynomolgi-infected Rhesus monkeys (Macaca mulatta).
Topics: Aminoquinolines; Animals; Antimalarials; Artemether, Lumefantrine Drug Combination; Artemisinins; Chloroquine; Chromatography, Liquid; Disease Models, Animal; Drug Combinations; Drug Therapy, Combination; Ethanolamines; Fluorenes; Humans; Macaca mulatta; Malaria; Male; Mass Spectrometry; Mefloquine; Plasma; Plasmodium cynomolgi; Primate Diseases; Quinine; Treatment Outcome | 2011 |
Humanized mouse model of glucose 6-phosphate dehydrogenase deficiency for in vivo assessment of hemolytic toxicity.
Topics: Aminoquinolines; Anemia, Hemolytic; Animals; Antimalarials; Chloroquine; Combined Modality Therapy; Dapsone; Dose-Response Relationship, Drug; Doxycycline; Drug Evaluation, Preclinical; Erythrocyte Count; Erythrocyte Transfusion; Female; Glucosephosphate Dehydrogenase Deficiency; Humans; Mefloquine; Mice; Mice, Inbred NOD; Mice, SCID; Primaquine; Pyrimethamine; Reproducibility of Results; Sensitivity and Specificity; Transplantation, Heterologous | 2013 |
Single-dose radical cure of Plasmodium vivax: a step closer.
Topics: Aminoquinolines; Antimalarials; Chloroquine; Female; Humans; Malaria, Vivax; Male | 2014 |
Mirincamycin, an old candidate for malaria combination treatment and prophylaxis in the 21st century: in vitro interaction profiles with potential partner drugs in continuous culture and field isolates.
Topics: Adolescent; Adult; Aged; Aminoquinolines; Antimalarials; Artemisinins; Child; Chloroquine; Clindamycin; Drug Interactions; Female; Humans; Male; Middle Aged; Parasitic Sensitivity Tests; Plasmodium falciparum; Young Adult | 2014 |
Cost-Effectiveness Analysis of Sex-Stratified
Topics: Adult; Afghanistan; Aminoquinolines; Anemia, Hemolytic; Antimalarials; Chloroquine; Cost-Benefit Analysis; Ethiopia; Female; Glucosephosphate Dehydrogenase Deficiency; Hemizygote; Heterozygote; Homozygote; Humans; Indonesia; Malaria, Vivax; Male; Mass Screening; Medication Adherence; Plasmodium vivax; Primaquine; Quality-Adjusted Life Years; Recurrence; Sex Factors; Vietnam | 2020 |